A Phase I Trial of Bortezomib in Combination with Everolimus for Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma.

Authors

Brian T Hill
Mitchell R Smith, George Washington University
Meredeth Shelley
Deepa Jagadeesh
Robert M Dean
Brad Pohlman
John W Sweetenham
Brian J Bolwell
Stephen D Smith

Document Type

Journal Article

Publication Date

3-1-2018

Journal

Leukemia & lymphoma

Volume

59

Issue

3

Inclusive Pages

690-694

DOI

10.1080/10428194.2017.1347932

Keywords

Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Drug Resistance, Neoplasm; Everolimus; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Remission Induction; Salvage Therapy; Survival Rate

APA Citation

Hill, B., Smith, M., Shelley, M., Jagadeesh, D., Dean, R., Pohlman, B., Sweetenham, J., Bolwell, B., & Smith, S. (2018). A Phase I Trial of Bortezomib in Combination with Everolimus for Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma.. Leukemia & lymphoma, 59 (3). http://dx.doi.org/10.1080/10428194.2017.1347932

Peer Reviewed

1